Spots Global Cancer Trial Database for recurrent lung small cell carcinoma

Every month we try and update this database with for recurrent lung small cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer	NCT03382561	Extensive Stage... Recurrent Lung ...	Carboplatin Cisplatin Etoposide Nivolumab	18 Years -	National Cancer Institute (NCI)
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer	NCT03382561	Extensive Stage... Recurrent Lung ...	Carboplatin Cisplatin Etoposide Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability	NCT04804644	Metastatic Lung... Metastatic Mali... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Memantine Hydro... Neurocognitive ... Stereotactic Ra... Whole-Brain Rad...	18 Years -	NRG Oncology
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer	NCT00453154	Extensive Stage... Recurrent Lung ...	Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer	NCT04919382	Extensive Stage... Metastatic Lung... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Atezolizumab Temozolomide	18 Years -	Big Ten Cancer Research Consortium
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs	NCT03896503	Bladder Small C... Extensive Stage... Extrapulmonary ... Limited Stage L... Platinum-Resist... Platinum-Sensit... Prostate Small ... Recurrent Lung ...	Berzosertib Biopsy Biospecimen Col... Computed Tomogr... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs	NCT03896503	Bladder Small C... Extensive Stage... Extrapulmonary ... Limited Stage L... Platinum-Resist... Platinum-Sensit... Prostate Small ... Recurrent Lung ...	Berzosertib Biopsy Biospecimen Col... Computed Tomogr... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer	NCT00453154	Extensive Stage... Recurrent Lung ...	Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability	NCT04804644	Metastatic Lung... Metastatic Mali... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Memantine Hydro... Neurocognitive ... Stereotactic Ra... Whole-Brain Rad...	18 Years -	NRG Oncology
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer	NCT05353439	Extensive Stage... Limited Stage L... Platinum-Resist... Platinum-Sensit... Recurrent Lung ...	Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Tazemetostat Hy... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	NCT03366103	Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So...	Navitoclax Vistusertib	18 Years -	National Cancer Institute (NCI)
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	NCT03366103	Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So...	Navitoclax Vistusertib	18 Years -	National Cancer Institute (NCI)
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer	NCT05353439	Extensive Stage... Limited Stage L... Platinum-Resist... Platinum-Sensit... Recurrent Lung ...	Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Tazemetostat Hy... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer	NCT05353439	Extensive Stage... Limited Stage L... Platinum-Resist... Platinum-Sensit... Recurrent Lung ...	Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Tazemetostat Hy... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: